DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ANTITHROMBIN-III CONCENTRATES IN SEPTIC SHOCK WITH DISSEMINATED INTRAVASCULAR COAGULATION

被引:277
|
作者
FOURRIER, F
CHOPIN, C
HUART, JJ
RUNGE, I
CARON, C
GOUDEMAND, J
机构
[1] CHRU LILLE,HOP B,HEMATOL LAB,LILLE,FRANCE
[2] CH VALENCIENNES,SERV REANIMAT POLYVALENTE,VALENCIENNES,FRANCE
[3] CTR REG TRANSFUS SANGUINE,LILLE,FRANCE
关键词
D O I
10.1378/chest.104.3.882
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Septic shock is frequently complicated by a syndrome of disseminated intravascular coagulation (DIC). Numerous uncontrolled clinical studies have reported that antithrombin III (ATIII) substitution might prevent DIC and death in septic shock. Methods: We conducted a randomized double-blind placebo-controlled trial in patients with a documented septic shock and DIC. The patients received either a placebo or ATIII (90 to 120 IU/kg in loading dose, then 90 to 120 IU/kg/d during 4 days). Administration of fresh frozen plasma, platelets, and fibrinogen concentrates was restricted to patients with hemorrhages and severe decreases in prothrombin time, platelet count, and fibrinogen levels. Results: Thirty-give patients entered the study (18 placebo, 17 ATIII). Both groups were well balanced for all demographic, hemodynamic, and biologic data. Three patients were excluded before the treatment allocation code was broken. In the ATIII group, ATIII levels were rapidly corrected and remained over normal levels until day 10, sequential protein C and protein S levels were not modified. The duration of DIC was significantly reduced; in the ATIII group, 64 percent of patients were cured of DIC at day 2, and 71 percent were cured at the end of treatment vs in the placebo group, 11 percent (p<0.01) and 33 percent (p<0.05), respectively. In the 32 included patients, the mortality in ICU was reduced by 44 percent in the ATIII group (p=0.22, NS). Care loads and transfusion requirements were not different. No side effect was observed. Conclusions: Mortality was reduced by 44 percent in this trial, but the difference did not reach the statistical significance. Circulating protein C and protein S levels were not modified by ATIII supplementation. High doses of ATIII concentrates significantly improved sepsis-induced DIC during septic shock. The trend toward improved survival suggests further randomized studies.
引用
收藏
页码:882 / 888
页数:7
相关论文
共 50 条
  • [31] ANTITHROMBIN-III PROTECTS AGAINST DISSEMINATED INTRAVASCULAR COAGULATION (DIC) IN KLEBSIELLA PERITONITIS
    EMERSON, TE
    LEACH, WJ
    REDENS, TB
    COLLINS, MS
    CLINICAL RESEARCH, 1987, 35 (01): : A143 - A143
  • [32] Influence of antithrombin and argatroban on disseminated intravascular coagulation parameters in a patient with septic shock
    Beyer, Jan
    Halbritter, Kai
    Schellong, Sebastian
    Weise, Matthias
    THROMBOSIS RESEARCH, 2009, 124 (03) : 383 - 386
  • [33] DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF KETAZOLAM IN ANXIETY
    BOWDEN, CL
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1978, 24 (02): : 170 - 178
  • [34] BROMOCRIPTINE IN MANIA - PLACEBO-CONTROLLED DOUBLE-BLIND TRIAL
    SMITH, AHW
    CHAMBERS, C
    NAYLOR, GJ
    BRITISH MEDICAL JOURNAL, 1980, 280 (6207): : 86 - 86
  • [35] NIFEDIPINE FOR EPILEPSY - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    LARKIN, JG
    BESAG, FMC
    COX, A
    WILLIAMS, J
    BRODIE, MJ
    EPILEPSIA, 1992, 33 (02) : 346 - 352
  • [36] Soy in hypercholesterolaemia: a double-blind, placebo-controlled trial
    P Puska
    V Korpelainen
    LH Høie
    E Skovlund
    T Lahti
    KT Smerud
    European Journal of Clinical Nutrition, 2002, 56 : 352 - 357
  • [37] DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF AMITRIPTYLINE IN BULIMIA
    ZITMAN, FG
    VANPUTTEN, PM
    KNOPPERTVANDEKLEIN, EAM
    EDELBROEK, P
    HULSING, M
    VECHTVANDENBERGH, R
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 1987, 32 (1-2) : 522 - 522
  • [38] A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
    Verstovsek, Srdan
    Mesa, Ruben A.
    Gotlib, Jason
    Levy, Richard S.
    Gupta, Vikas
    DiPersio, John F.
    Catalano, John V.
    Deininger, Michael
    Miller, Carole
    Silver, Richard T.
    Talpaz, Moshe
    Winton, Elliott F.
    Harvey, Jimmie H., Jr.
    Arcasoy, Murat O.
    Hexner, Elizabeth
    Lyons, Roger M.
    Paquette, Ronald
    Raza, Azra
    Vaddi, Kris
    Erickson-Viitanen, Susan
    Koumenis, Iphigenia L.
    Sun, William
    Sandor, Victor
    Kantarjian, Hagop M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (09): : 799 - 807
  • [39] PLACEBO-CONTROLLED DOUBLE-BLIND TRIAL OF MIANSERIN HYDROCHLORIDE
    SMITH, AHW
    NAYLOR, GS
    MOODY, JP
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1978, 5 : S67 - S70
  • [40] Double-blind placebo-controlled trial of topiramate in SUNCT
    Cohen, Anna
    Goadsby, P.
    Matharu, M.
    CEPHALALGIA, 2007, 27 (06) : 758 - 758